Patients receiving onabotulinumtoxinA treatment for chronic migraine (CM) may have coexisting diseases warranting multi-indication use of onabotulinumtoxinA. However, data on safety and treatment patterns for concomitant treatment of CM and other diseases are limited. SYNCHRONIZE was a phase 4, multicenter, retrospective study that explored the safety of onabotulinumtoxinA treatment for ≥ 2 therapeutic (non-aesthetic) indications within 3 months. The observation period of interest was approximately 6 months before and 24 months after receiving treatment for the second indication. The primary outcome was treatment-emergent adverse events (TEAEs) occurring within 6 months. Results are reported descriptively and stratified by treatment indications. This analysis focuses on patients treated for CM and ≥ 1 other onabotulinumtoxinA indication. A total of 183 patients had CM and ≥ 1 other onabotulinumtoxinA indication (CM + cervical dystonia [CD], n = 121; CM + oromandibular dystonia [OD] ± blepharospasm [BS], n = 17; CM + BS or hemifacial spasm [HS], n = 13; CM + CD + other movement disorders [MD], n = 11; CM + spasticity [SP] or focal dystonia [FD], n = 10; CM + hyperhidrosis [HH] ± other MD, n = 5; CM + overactive bladder [OAB] or neurogenic detrusor overactivity [NDO], n = 4; CM + other MD, n = 2). The 3-month mean cumulative onabotulinumtoxinA dose ranged from 163.4 U (CM + OD ± BS) to 396.2 U (CM + SP or FD), and most patients received treatment for their first and subsequent indications within 24 h. The proportion of patients with ≥ 1 TEAE in the 6 months post-index was 23.5

The increasing incidence of stroke among young adults challenges the conventional belief that strokes predominantly affect the elderly. This case report explores the complicated intersection of paroxysmal nocturnal hemoglobinuria (PNH) and strokes in young individuals, examining diagnostic challenges, underlying mechanisms, and the need to recognize this less-explored association for timely intervention. Here, we describe a case of a young male who presented to intensive care with a stroke against a background of recurrent thrombosis and was diagnosed with PNH. While conventional risk factors like hypertension and atherosclerosis are commonly associated with strokes, this case report sheds light on the less-explored connection between PNH and strokes in young adults, emphasizing the need to unravel these seemingly unrelated conditions for enhanced diagnostic precision and improved management.

Introduction This observational study explores the Peripheral Perfusion Index (PPI) as a predictor of hypotension and mortality in sepsis. By correlating PPI with clinical outcomes, it assesses its potential for early diagnosis and goal-directed therapy, aiming to improve sepsis management beyond traditional blood pressure-based methods for better patient outcomes. Objectives To evaluate the role of the PPI in the early diagnosis and targeted treatment of septic shock, providing insights for improving clinical management and early intervention. Material and method This prospective study conducted at a tertiary medical centre, a medical college in Bihar, compares septic shock outcomes between Group 1 (the PPI group), with septic shock diagnosed with PPI <1.4; treatment guided by PPI >2, and Group 2 (the control group), diagnosed by traditional shock criteria (systolic blood pressure <90 mmHg or >40 mmHg drop from baseline) with standard bundle treatment. Result PPI-guided therapy significantly improved hemodynamic stabilization, reduced hypotension (28% vs. 50%), decreased mortality (12.5% vs. 31.3%), and shortened ICU stays (5 ± 2 vs. 8 ± 3 days) compared to traditional shock criteria. PPI demonstrated strong predictive value for hypotension (area under the receiver operating characteristic curve (AUROC) 0.86) and mortality (AUROC 0.89), supporting its clinical utility in sepsis. Conclusion This study confirms PPI's reliability in septic shock management, advocating a shift from mean arterial pressure (MAP)-focused to PPI-guided therapy for better outcomes.

Background Trauma remains a leading global cause of mortality, particularly in low-resource settings. Advanced Trauma Life Support (ATLS) training offers a standardized approach to trauma care, yet its impact in India remains underexplored. This study evaluates the effectiveness of ATLS training in reducing preventable trauma-related deaths and improving clinical decision-making at a tertiary care center in Bihar, India. Methods This mixed-methods cohort study was conducted from October 2021 to December 2024 and included 200 trauma patients aged ≥18 years. Patients were divided into two groups: pre-ATLS (retrospective; October 2021 to July 2024) and post-ATLS (prospective; August 2024 to December 2024). Mortality rates, trauma management errors, and survival outcomes were analyzed using Kaplan-Meier survival curves, chi-square tests, logistic regression models, and Cox proportional hazards regression. Additionally, structured interviews with healthcare providers supplemented the quantitative findings. Statistical analyses were performed using IBM SPSS Statistics for Windows, Version 20.0 (Released 2019; IBM Corp., Armonk, NY, USA) and R software, Version 4.1.2 (R Foundation for Statistical Computing, Vienna, Austria), with significance set at p < 0.05. Results ATLS training significantly reduced preventable deaths (from 30% to 15%) and potentially preventable deaths (from 40% to 25%). Trauma management errors, including delayed diagnoses and protocol deviations, also decreased post-training. Kaplan-Meier analysis demonstrated improved survival, while Cox regression identified ATLS training as an independent predictor of survival (HR = 0.62, 95% CI: 0.45-0.85, p = 0.003). Healthcare providers reported greater confidence in trauma assessment but highlighted concerns regarding accessibility, cost, and the need for refresher courses. Conclusions ATLS training enhances trauma care by reducing preventable mortality, minimizing errors, and boosting provider confidence. Expanding ATLS programs, particularly in resource-limited settings, is recommended. Future research should focus on long-term patient outcomes and the cost-effectiveness of ATLS implementation.

Sepsis is a leading cause of acute respiratory distress syndrome (ARDS) worldwide. Effective fluid management strategies are essential for treating these patients. This research assesses the practical implementation and outcomes of restrictive versus liberal fluid management approaches in ARDS caused by sepsis. The aim of the study is to assess the clinical outcomes linked to various fluid management strategies in real-world scenarios, providing insights to optimize clinical practices and develop personalized treatment protocols for very sick patients with ARDS. This retrospective observational study included 120 patients with ARDS due to sepsis. They were treated at a tertiary care center in India between June 2022 and January 2024. Patients were categorized into restrictive fluid groups (RGs) and liberal fluid groups (LGs). 28-day mortality was considered the primary outcome, while the secondary outcomes included the period of ventilatory support, intensive care unit (ICU) length of stay, incidence of renal failure, need for renal replacement therapy (RRT), and new organ dysfunction. Patients in the RG had a significant decline in 28-day mortality (25% vs. 40%, P = 0.043) and shorter period of ventilatory support (8 days vs. 12 days, P = 0.001) compared to the LG. ICU length of stay was also reduced (12 days vs. 16 days, P = 0.028). The incidence of renal failure or need for RRT was insignificant between groups. However, the incidence of new organ dysfunction was significant between groups. Restrictive fluid management in ARDS resulting from sepsis has been linked to better survival rates, shorter periods of mechanical ventilation, and reduced ICU stays. These results advocate for adopting restrictive fluid strategies.

OnabotulinumtoxinA (onabotA) is approved for the treatment of various therapeutic indications, which require retreatment. In clinical practice, many patients receive onabotA for multiple therapeutic indications concomitantly over extended time periods; however, there is limited long-term utilization and safety data for treating comorbid indications. SYNCHRONIZE, a 2-year, multicenter, retrospective observational chart review study in 10 US clinics, describes onabotA real-world utilization and safety in adults treated for ≥2 therapeutic indications within repeating 3-month periods for up to 7 treatments. This analysis assessed the long-term onabotA safety profile for multiple therapeutic indications by analyzing the incidence of treatment-emergent adverse events (TEAEs). Of 279 patients treated for ≥2 different therapeutic indications across all treatment combination groups in Period1, there was a gradual decrease to 80 patients at the last treatment period. The overall mean onabotA treatments over the study period was 9.3 (range: 2-48). Across treatment periods, most patients had a treatment interval between different indications of ≤24 h (range: 62-98 %) and received ≥200-<400U of cumulative 3-month dosages for multiple indications (range: 43 %-50 %) with a mean 3-month dose from 231.8 to 287.0 U. In total, 28.7 % of patients reported ≥1 TEAE after Period1; this proportion remained broadly constant across treatments (range: 28.3-31.8 %). Overall, the most common TEAEs across treatments were UTIs (range: 0.7-5.7 %), neck pain (range: 3.7-9.1 %), headache (range: 2.9-6.5 %), and migraine (range: 2.5-6.4 %). There was no apparent trend between TEAE incidence and treatment intervals nor cumulative 3-month dose categories for multiple indications. No patients were determined to have lack of effect based on clinical objective measurement. OnabotA showed a safety profile with no new signals in patients treated concomitantly for ≥2 therapeutic indications over repeat treatments up to 2 years. TEAEs across treatment periods were commonly related to the site of injection and were consistent with those previously reported for individual indications.

Transmission losses are commonplace in any power system, often arising from changes in load that can be abrupt and undetermined. Such changes from actual or real values pose a danger, as they may cause power loss and damage to the power system. To prevent these issues and avoid excess loss in the transmission, various types of HVDC systems are used as they can carry huge amounts of power with the usage of a smaller number of conductors. Faults may occur in this HVDC system hence a signal processing technique called Wavelet transform is used which detects the fault signal and ensures the credibility of the power system.

Background: Traumatic brain injury (TBI) is a major cause of mortality among young individuals, accounting for 65% of deaths in road traffic accidents. Paroxysmal sympathetic hyperactivity (PSH) is a common syndrome associated with TBI. This study represents the first prospective investigation aimed at assessing the impact of gabapentin on TBI patients, focusing on the prevention of secondary brain injury and brain edema while enhancing the Glasgow Coma Scale (GCS). Materials and methods: The study was conducted from September 2019 to July 2021 after receiving ethical committee approval. It included adult ICU patients (>= 18 years) with moderate and severe GCS. Patients below 18 years, death within 48 hours, non -consenting, pregnant females, and individuals allergic to gabapentin were excluded from the study. Patients were randomly allocated in two groups: study group received 300 mg of gabapentin orally twice daily and control group received multivitamin tablets twice daily. The treatment period spanned 2 weeks. Follow-up occurred in the ICU and continued for up to 3 months post -discharge, including telephonic conversations. Results: About 60 patients were involved for analysis. Significant differences were found in GCS change from admission to discharge, Glasgow Outcome Scale (GOS) at 30 and 90 days, PSH episodes, and sedation bolus per day. Glasgow Coma Scale change was 53% in the study group compared with 25% in the control group (p = 0.009). Mortality was significantly lower in the study group. Glasgow Outcome Scale change between 30 and 90 days showed a 25% improvement in cases and no change in controls (p = 0.001). Conclusion: This pioneering study underscores the potential of gabapentin in managing traumatic brain injuries.

OnabotulinumtoxinA (onabotA) is approved in the US for 12 therapeutic indications. Real-world data on onabotA multi-indication use are limited, often leading to delayed or reduced treatment. This study provides real-world evidence on the safety of onabotA when treating multiple indications concomitantly. SYNCHRONIZE was a multicenter, retrospective, chart-review study evaluating onabotA’s safety for adults treated for ≥2 therapeutic indications within a 3-month period. The primary outcome was treatment-emergent adverse events (TEAEs) within 6 months post-treatment. A total of 279 patients were included. The most common concomitant indications treated were cervical dystonia and chronic migraine (43.4%). The average 3-month cumulative dose for multiple indications was 282.2 U. The treatment interval for multiple indications was ≤24 h for most patients (62.4%). Overall, 28.7% of patients reported ≥1 TEAE with no apparent trends in TEAEs and dose interval or cumulative dose. Reported TEAEs included UTI (5.7%), neck pain (5.0%), and headache (4.3%). No patient had a lack of effect according to clinical objective measurements. SYNCHRONIZE described the real-world safety of onabotA for patients treated concomitantly for ≥2 indications within a 3-month period. TEAEs were generally consistent with the known safety profiles of individual indications. No new safety signals were identified).

Islanding is a significant obstacle along with excessive penetration of DG sources. The islanding could cause harm to the customers and their equipment's. The IEEE 1547 DG interconnection regulations stipulate that the DG must be disconnected and the islanding must be observed within two seconds. Basically, this paper presents a novel method for detecting islanding based upon image pattern recognition using random forest (RF) classification technique is proposed. Images are utilized to derive the local binary pattern (LBP) characteristics so as to identify non-islanding as well as islanding events. Hence, the time series signal is obtained and transformed into spectrogram images at the point of common connection. These images are utilized to extract the features using histogram of oriented gradient, which is then utilized as a feature vector input for the RF classifier for training as well as testing. It uses rate of change of negative sequence voltage parameter to derive spectrogram image. The RF classifier's effectiveness is assessed with 5-fold cross-validations. The results from classification demonstrates that detection of islanding using RF classifier and LBP feature being used for image pattern recognition achieved excellent results with 98.25% accuracy and detection time of 182 milliseconds.

According to prescribing information, potency units are not interchangeable between botulinum toxin A products. This exploratory study compared real-world dosing and utilization of onabotulinumtoxinA and abobotulinumtoxinA in adults with upper limb spasticity. In this retrospective study, 101 clinicians provided chart data via online surveys for 215 US post-stroke patients treated for upper limb spasticity with >= 3 onabotulinumtoxinA or abobotulinumtoxinA doses (phase 1: 9/18/2020-12/10/2020; phase 2: 9/30/2021-12/7/2021). Most participating clinicians were physicians (70.3%) specializing in neurology (71.3%) or physiatry (20.8%). In the onabotulinumtoxinA (n = 107) and abobotulinumtoxinA (n = 108) groups, similar to 75% of patients had moderate-to-severe spasticity. A range of onabotulinumtoxinA:abobotulinumtoxinA dose ratios (1:2.2 [95% CI: 1.8, 2.6] to 1:4.1 [95% CI: 3.0, 6.0]) was observed across muscles. For the most recent dose, mean number of muscles injected was greater for onabotulinumtoxinA (4.3) versus abobotulinumtoxinA (3.1; P = 0.0003). For onabotulinumtoxinA versus abobotulinumtoxinA, the proportion of injections was 81.3% versus 63.9% (P = 0.0067) in forearm muscles and 23.4% versus 3.7% (P = 0.0001) in hand muscles. Mean injection intervals were similar (onabotulinumtoxinA: 102.0 days; abobotulinumtoxinA: 99.1 days). Differences in real-world dosing and utilization of onabotulinumtoxinA and abobotulinumtoxinA for upper limb spasticity were observed. There was no standard dose-conversion ratio, consistent with each product's prescribing information.